|
Lin Cai, Zong-Li
Zheng, Department of Epidemiology, Fujian Medical University,
Fuzhou 350004, Fujian Province, China
Zuo-Feng Zhang, Department of Epidemiology, UCLA School of
Public Health, Los Angeles, CA, USA
Supported by the Natural Science Foundation of Fujian
Province, China, No. C0410016, and the Foundation for the Author of
National Excellent Doctoral Dissertation of PR China, No. 200157
Correspondence to: Lin Cai, M.D., Ph.D., Department of
Epidemiology, UCLA School of Public Health, 71-225 CHS, Box 951772,
10833 Le Conte Avenue, Los Angeles, CA 90095-1772, USA.
lcaiin@ucla.edu
Telephone: +1-310- 825-8418
Received: 2004-08-31
Accepted: 2004-12-01
Abstract
Aim: Genetic
polymorphisms of drug-metabolizing enzymes have recently been shown
to affect susceptibility to chemical carcinogenesis. Cytochrome P450
2E1 (CYP2E1) enzyme catalyzes the metabolism of many
procarcinogens, such as N-nitrosamines and related compounds.
The gene coding for this enzyme is polymorphic and thus may play a
role in gastric cardia cancer (GCC) etiology. In this hospital-based
case-control study, we evaluate the relationship between genetic
polymorphisms of CYP2E1 and the risk of GCC.
Methods: The
study subjects comprised 159 histologically confirmed GCC cases
identified via hospital cancer registry and surgical records at five
hospitals in Fuzhou, Fujian Province, China, between April and
November 2001. Controls were 192 patients admitted to the same
hospitals for nonmalignant conditions. The genotypes of CYP2E1 were
detected by a PCR-based RFLP assay. The odds ratios were estimated
by logistic regression analyses and were adjusted for potential
confounding factors.
Results: The
distribution of three genotypes of CYP2E1 in GCC cases and
controls was significantly different (c2
= 16.04, P<0.01). The frequency
of the CYP2E1 (c1/c1) genotype in GCC cases and
controls was 60.4% and 40.1%, respectively. The CYP2E1 (c1/c1)
genotype was associated with an increased risk for GCC (the adjusted
(OR) was 2.37, 95% confidence interval (CI): 1.52-3.70). Subjects
who carried the CYP2E1 (c1/c1) genotype and were
habitual smokers were at a significantly higher risk of developing
GCC (OR = 4.68, 95%CI: 2.19-10.04) compared with those who had the CYP2E1
(c1/c2 or c2/c2) genotype and did not smoke.
Conclusion:
These results suggest that the CYP2E1 genotype may influence
individual susceptibility to development of GCC, and that the risk
increases significantly in smokers.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
Key words: Cardia cancer; Genetic susceptibility; CYP2E1
Cai L, Zheng ZL, Zhang ZF. Cytochrome p450 2E1 polymorphisms and the
risk of gastric cardia cancer. World J Gastroenterol 2005; 11(12): 1867-1871
http://www.wjgnet.com/1007-9327/11/1867.asp
INTRODUCTION
Gastric cardia cancer (GCC) has shown a rapid increase in
incidence in many developed countries in the last 20 years[1-5].
Despite a steady fall in incidence of non-cardia cancer, gastric
cancer remains a significant cause of mortality and morbidity
worldwide[6,7].
Epidemiological studies have reported that exposure to N-nitrosamines
and related compounds may be important factors for gastric
carcinogenesis[8-11].
Environmental chemical carcinogens require metabolic activation by
host enzymes[12-15].
CYP2E1 is of critical importance in the metabolic activation
of many low-molecular-weight carcinogens, including N-nitrosamines[16].
The gene coding for this enzyme is polymorphic and thus may also be
involved in this process[17,18].
Several studies described significant associations between CYP2E1
polymorphisms and the incidences of human cancer, e.g., in
esophageal cancer[19],
lung cancer[20],
nasopharyngeal carcinoma[21]
and colorectal cancer[22-24].
In contrast, other studies showed no association[25-27].
To date there have been no studies on the relationship of this
genotype to GCC risk[28].
We hypothesized that if N-nitroso compounds
play a role in GCC, and smoking is a
significant source of exposure for these compounds, then the
polymorphisms may be associated with this disease and may modify the
association of smoking with GCC. In the present study, we evaluated
the possible relevance of Cytochrome P4502E1 polymorphisms to GCC.
MATERIALS AND METHODS
Study subjects
The cardia cancer group (n = 159) consists of all
inpatients who were diagnosed with primary cardia cancer and were
identified between April and November of 2001 from five hospitals:
First-accessory hospital of Fujian Medical University, Xiehe
hospital-affiliated Fujian Medical University, Fujian provincial
hospital, Tumor hospital of Fujian province and Zong hospital of
Fuzhou. Frequency matched controls (n = 192) were
continuously recruited by gender and age (3 years) during the same
period in the same hospitals, and were confirmed to be cancer-free
and with no history of cancer. All subjects were ethnic Han Chinese
and residents of Fuzhou, Fujian province, China.
Interview
In-person interviews were conducted at the hospitals by
trained interviewers. A structured questionnaire was composed of
items such as general characteristics, personal medical history,
family cancer history, smoking and drinking history, and dietary
factors. Blood samples were collected from each participant for
genotyping.
Genotyping
DNA was extracted from the coagulated blood using DNAzol reagent
according to the manufacturer's
instructions. Genotyping for polymorphisms of CYP2E1 (GenBank
ID: NM_000773) was detected using the PCR-RFLP technique. PCR
products were generated by using 100 ng of genomic DNA in 25 mL
volume reactions containing 10 mmol/L Tris-HCL
(pH 8.3), 50 mmol/L KCL, 2.0 mmol/L MgCl2,
0.2 mmol/L each dNTP, 0.25 mmol/L
each outer oligonucleotide primer (forward,
5'-CCAGTCGAGTCT-ACATTGTCA-3'; reverse, 5'-AGACCTCCACATT-GACTAGC-3')
and 1.5 U Taq DNA polymerase. The PCR amplification consisted
of an initial 5-min incubation at 94 ℃,
followed by 35 cycles of denaturing at 94 ℃
for 30 s and annealing at 58 ℃
for 30 s, with an extension at 72 ℃
for 1 min. The reaction was terminated after a final extension
of 10 min at 72 ℃.
The PCR-amplified DNA fragments including the polymorphic site were
digested with the restriction enzymes PstI at 37 ℃
overnight, and subjected to electrophoresis on 2.0% agarose gel
containing 0.5 mg/mL
ethidium bromide for visualization under UV light[29].
A combination of 435- and 118-bp fragments represented c2/c2 genotype;
a combination of 553-, 435- and 118-bp fragments represented c1/c2;
only a 553-bp fragment represented c1/c1. To ensure quality
control, genotyping was performed with blinding to case-control
status.
Statistical analysis
c2
were used to evaluate case-control differences in the distribution
of genotypes. Unconditional logistic regression was used to estimate
the odds ratios and 95%CI, and were adjusted for potential
confounding factors.
RESULTS
The relevant characteristics of the study subjects are shown in
Table 1. Eighty-one percent of cases and 72.9% of controls were
male. The distribution of age and gender among cases and controls
were not statistically different. GCC cases (59.7%) had a higher
proportion of low educational level than controls (46.4%). Detailed
results for GCC risk factors in this study have been published
elsewhere.
The overall genotype frequencies for c1/c2,
c2/c2, and c1/c1 of CYP2E1 were 47.58% (157/351),
3.13% (11/351), and 49.29% (173/351), respectively. The frequency of
the C1 and C2 alleles in the control group was 68% and 31%,
respectively. As shown in Table 2, 60.4% (n = 96) of cases
and 40.1% (n = 77) of controls had the c1/c1 genotype.
The frequency of the CYP2E1 c1/c1 genotype was significantly
different between the GCC cases and the controls (c2
= 16.04, P<0.01), and the risk
for the c1/c1 homozygous subjects to have GCC is three-fold
times greater than it is for the c2/c2 homozygous and c1/c2
heterozygous subjects (OR = 2.37, 95%CI: 1.52-3.70).
Of all subjects, 57.2% (91/159) of cases and
43.8% (84/192) of controls were smokers (OR = 1.58,
95%CI:0.96-2.61). To further explore the relationship of smoking, CYP2E1
polymorphisms and GCC, we performed an analysis of association
between smoking and the CYP2E1 genotype, separately in cases
and controls. Table 3 presents the joint effects on GCC. The
proportion of smokers with the CYP2E1 c1/c1 genotype was
significantly higher in patients with GCC (61/159, 38.36%) than in
the controls (24/192, 12.50%). The greatly elevated risk associated
with smoking was observed in the CYP2E1 c1/c1 genotype group
(taking non-smokers with the c1/c2 or c2/c2 genotype
as the reference group). Cigarette smoking in subjects with the c1/c1
genotype was associated with a four-fold higher risk (OR = 3.94,
95%CI: 1.60-9.67) compared to their non-smoking counterparts. There
was an increasing trend in ORs with the number of cigarettes smoked
per day (OR: 2.59 for <20 cigarettes a day; OR: 4.17 for ≥20
cigarettes a day). The strongest association with the GCC risk (OR =
8.44, 95%CI: 2.58-27.59) was observed among individuals carrying the
CYP2E1 c1/c1 genotype and having a long history of smoking (≥30
years), even after adjustment for potential confounding factors.
Table 1
Select characteristics of cardia cancer cases (n =
159) and controls (n = 192)
| Variable |
Cases |
Controls |
P |
| n |
(%) |
n |
(%) |
| Age
(yr) |
|
|
|
|
|
| ≤59 |
62 |
39.0 |
93 |
48.4 |
|
| 60-69 |
61 |
38.4 |
60 |
31.3 |
|
| ≥70 |
36 |
22.6 |
39 |
20.3 |
0.196 |
| Sex |
|
|
|
|
|
| Female |
30 |
18.9 |
52 |
27.1
|
|
| Male |
129 |
81.1 |
140 |
72.9 |
0.070 |
| Education
(yr) |
|
|
|
|
|
| <12 |
95 |
59.7 |
89 |
46.4 |
|
| ≥12 |
64 |
40.3 |
103 |
53.6 |
0.012 |
Table 2
Association of CYP2E1 polymorphisms with cardia cancer
risk
| CYP2E1 |
Cases |
Controls |
OR
(95%CI)1 |
| N |
% |
N |
% |
| C1/c2 |
57 |
35.8 |
110 |
57.3 |
1.0 |
| C2/c2 |
6 |
3.8 |
5 |
2.6 |
|
| C1/c1 |
96 |
60.4 |
77 |
40.1 |
2.37 (1.52-3.70) |
1Adjusted
for age (continuous), gender and educational level. c2
= 16.04, bP<0.01.
Table
3 Associations
of cardia cancer risk with joint distribution of CYP2E1 genotypes
and smoking status
| Smoking
status |
CYP2E1 |
Cases |
Controls |
OR
(95%CI)1 |
OR
(95%CI)2 |
| n |
% |
n |
% |
| Smoking |
|
|
|
|
|
|
|
| Never |
c1/c2
or c2/c2 |
33 |
20.75 |
55 |
28.65 |
1 |
1
|
| Ever |
C1/c1 |
35 |
22.01 |
53 |
27.60 |
1.05
(0.561.99) |
1.03
(0.522.06) |
| Ever |
c1/c2
or c2/c2 |
30 |
18.87 |
60 |
31.25 |
0.85
(0.401.78) |
0.91
(0.392.14) |
| Ever |
C1/c1 |
61 |
38.36 |
24 |
12.50 |
4.68
(2.1910.04) |
3.94
(1.609.67)
|
| Daily
consumed cigarettes |
|
|
|
|
|
|
|
| 1-19 |
c1/c2
or c2/c2 |
8 |
5.03 |
15 |
7.81 |
0.81
(0.272.39) |
0.62
(0.182.16) |
| 1-19 |
C1/c1 |
9 |
5.66 |
6 |
3.13 |
2.99
(0.8810.19) |
2.59
(0.5412.45) |
| ≥20 |
c1/c2
or c2/c2 |
22 |
13.84 |
45 |
23.44 |
0.90
(0.411.98) |
1.04
(0.412.67) |
| ≥20 |
C1/c1 |
52 |
32.70 |
18 |
9.38 |
5.34
(2.3811.95) |
4.17
(1.6310.63) |
| Smoking
duration (yr) |
|
|
|
|
|
|
|
| 1-29 |
c1/c2
or c2/c2 |
10 |
6.29 |
25 |
13.02 |
0.71
(0.271.87) |
0.82
(0.272.49) |
| 1-29 |
C1/c1 |
19 |
11.95 |
18 |
9.38 |
2.10
(0.855.21) |
1.99
(0.616.49) |
| ≥30 |
c1/c2
or c2/c2 |
20 |
12.58 |
35 |
18.23 |
1.10
(0.472.57) |
1.00
(0.372.69) |
| ≥30 |
C1/c1 |
42 |
26.42 |
6 |
3.13 |
13.32
(4.5039.45) |
8.44
(2.5827.59) |
1Odds
ratios adjusted for age (continuous), gender and educational level. 2Odds
ratios adjusted for age (continuous), gender, educational level,
family cancer history, vegetables and fruit consumption, picked and
salted food consumption, alcohol consumption, and refrigerator use.
DISCUSSION
Gastric cancer is a common cancer in China as well as the rest
of the world. Epidemiological studies have shown an association
between nitrosamine exposure and increased risk of gastric
cancer[30].
Besides diet, exogenous exposure to nitrosamines can occur through
use of tobacco products[31,32].
Recently, several studies have found a higher relative risk of
smoking for GCC[33-35].
A new prospective study found that the relative risk of current
smokers was 2.4 for cardia cancer and 1.7 for all sites[36,37].
In our previous report, we found an elevated risk of gastric cancer
with smoking habit, more distinct with the GCC than non-GCC.
Gastric carcinogenesis is a multistep process in which genetic and
environmental factors interact in the development of cancer.
Interindividual genetic differences in susceptibility to chemical
carcinogens are among the most important host factors in human
cancer[38-40].
It has been proposed that various host factors affect susceptibility
to cancer, even following the same exposure to environmental
carcinogenic factors[41-43].
CYP2E1 is one of the main enzymes for bioactivation of
tobacco-related substances, and its polymorphisms may be associated
with or be risk factors for various forms of cancers[44-46].
Our present data demonstrate that individuals carrying the CYP2E1
c1/c1 genotype were at increased risk for GCC. Moreover,
subjects who carry this genotype and have a history of heavy
cigarette smoking were at markedly greater increased risk (more than
four-fold) for GCC. These results suggested that the interaction of
the CYP2E1 polymorphism with smoking has a great influence on
susceptibility to GCC. To our knowledge, this is the first study to
examine the association of CYP2E1 polymorphisms with GCC.
The development of GCC may be associated with N-nitroso
compound exposures. Tobacco smoke contains hundreds of known and
probable human carcinogens[47].
Specific chemicals in tobacco smoke include polycyclic aromatic
hydrocarbons (PAHs), N-nitrosamines, aromatic amines and
others[48,49].
A critical review summarizing data for tobacco constituents proposed
that tobacco-specific nitrosamines and PAHs are classes of compounds
that mostly affect human cancer risk[50,51].
Nitrosamines require metabolic activation by cytochrome P450 enzymes
before they bind to DNA, initiating the carcinogenic process[52].
Evidence exists that carcinogen-DNA adduct levels are affected by
genetic predispositions. Studies indicate that carcinogen-DNA
adducts are related to cancer risk[53].
Smoking-related DNA adducts have been detected in human gastric
cancer of smokers. CYP2E1 is a key-activating enzyme because
it catalyzes the a-hydroxylation of many nitrosamines. Its activity
shows significant interindividual variation, due in part to
inherited alterations of the structural gene[54].
The frequency of the c1/c1 genotype among controls in this
study is similar to previously published estimates in Chinese
populations. Tan et al.[55],
studied 150 cases with esophageal cancer, 146 cases with esophageal
dysplasia, and 150 normal controls in Linxian, China and found that
the distribution of CYP2E1 c1/c1 allele frequency was
significantly different between controls (44.0%) and cases with
cancer (71.3%) or cases with dysplasia (70.6%).
In conclusion, the present case-control study suggested that the
individuals carrying the CYP2E1 c1/c1 genotype have a higher
risk for GCC. The CYP2E1 c1/c1 genotype is considered as one
of the possible susceptibility genes, and the risk increases
significantly in smokers. Because of the limited number of subjects,
this study does not have appropriate power to detect the interaction
between smoking and other factors. Further studies are required to
clarify the relationship between CYP2E1 and GCC
susceptibility.
ACKNOWLEDGEMENTS
We are grateful to all patients who kindly agreed to participate in
this study and the physicians and clinical staff for their
collaboration.
REFERENCES
1 Nguyen
AM, Luke CG, Roder D. Comparative epidemiological
characteristics of esophageal adenocarcinoma and
other cancers of
the oesophagus and gastric cardia. Asian Pac J Cancer Prev
2003; 4: 225231
2 Bareiss
D, Stabenow R, Muller R, Eisinger B, Stegmaier C, Daubler P,
Zeitz M, Scherubl H. Current epidemiology
of carcinoma of the
esophagus and cardia in Germany. Dtsch Med Wochenschr 2002; 127:
13671374
3 Blaser
MJ, Saito D. Trends in reported adenocarcinomas of the
oesophagus and gastric cardia in Japan.
Eur J Gastroenterol
Hepatol 2002; 14: 107113
4 Kocher
HM, Linklater K, Patel S, Ellul JP. Epidemiological study of
oesophageal and gastric cancer in southeast
England. Br J Surg
2001; 88: 12491257
5 Botterweck
AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends
in incidence of adenocarcinoma
of the oesophagus and gastric cardia
in ten European countries. Int J Epidemiol 2000; 29:
645654
6 Roder
DM. The epidemiology of gastric cancer. Gastric Cancer
2002; 5(Suppl 1): 511
7 Torrado
J, Santisteban A, Ruiz-Ederra J. Genetic susceptibility to
gastric cancer. Hepatogastroenterology
2001; 48:
15441547
8 Correa
P, Piazuelo MB, Camargo MC. The future of gastric cancer
prevention. Gastric Cancer
2004; 7: 916
9 Yamashita
S, Nomoto T, Abe M, Tatematsu M, Sugimura T, Ushijima T.
Persistence of gene expression changes
in stomach mucosae induced by
short-term N-methyl-N-nitro-N-nitrosoguanidine treatment and their
presence in
stomach cancers. Mutat Res 2004; 549:
185193
10 Abe
M, Yamashita S, Kuramoto T, Hirayama Y, Tsukamoto T, Ohta T,
Tatematsu M, Ohki M, Takato T, Sugimura T,
Ushijima T. Global
expression analysis of N-methyl-N-nitro-N-nitrosoguanidine-induced
rat stomach carcinomas using
oligonucleotide microarrays. Carcinogenesis
2003; 24: 861867
11 Viani
F, Siegrist HH, Pignatelli B, Cederberg C, Idstrom JP, Verdu EF,
Fried M, Blum AL, Armstrong D. The effect
of intra-gastric acidity
and flora on the concentration of N-nitroso compounds in the
stomach.
Eur J Gastroenterol Hepatol 2000; 12: 165173
12 Sasaki
M, Tanaka Y, Okino ST, Nomoto M, Yonezawa S, Nakagawa M,
Fujimoto S, Sakuragi N, Dahiya R.
Polymorphisms of the CYP1B1 gene
as risk factors for human renal cell cancer. Clin Cancer Res
2004; 10: 20152019
13 Thier
R, Bruning T, Roos PH, Rihs HP, Golka K, Ko Y, Bolt HM. Markers
of genetic susceptibility in human
environmental hygiene and
toxicology: The role of selected CYP, NAT and GST genes. Int J
Hyg Environ Health
2003; 206: 149171
14 Schoket
B, Papp G, Levay K, Mrackova G, Kadlubar FF, Vincze I. Impact of
metabolic genotypes on levels of
biomarkers of genotoxic exposure. Mutat
Res 2001; 482: 5769
15 Williams
JA. Single nucleotide polymorphisms, metabolic activation and
environmental carcinogenesis: Why
molecular epidemiologists should
think about enzyme expression. Carcinogenesis 2001; 22:
209214
16 Bolt
HM, Roos PH, Thier R. The cytochrome P-450 isoenzyme CYP2E1 in
the biological processing of industrial
chemicals: Consequences for
occupational and environmental medicine. Int Arch Occup Environ
Health
2003; 76: 174185
17 Lucas
D, Ferrara R, Gonzales E, Albores A, Manno M, Berthou F.
Cytochrome CYP2E1 phenotyping and genotyping in
the evaluation of
health risks from exposure to polluted environments. Toxicol Lett
2001; 124: 7181
18 Chen
SY, Liu TY, Shun CT, Wu MS, Lu TH, Lin JT, Sheu JC, Santella RM,
Chen CJ. Modification effects of GSTM1,
GSTT1 and CYP2E1
polymorphisms on associations between raw salted food and incomplete
intestinal metaplasia
in a high-risk area of stomach cancer. Int
J Cancer 2004; 108: 606612
19 Xing
D, Tan W, Lin D. Genetic polymorphisms and susceptibility to
esophageal cancer among Chinese population
(review). Oncol Rep
2003; 10: 16151623
20 Li Z,
Tan W, Shao K. Susceptibility to lung cancer in Chinese is
associated with genetic polymorphism in cytochrome
P4502E1. Zhonghua
Zhongliu Zazhi 2000;
22: 57
21 Hildesheim
A, Anderson LM, Chen CJ, Cheng YJ, Brinton LA, Daly AK, Reed CD,
Chen IH, Caporaso NE, Hsu MM,
Chen JY, Idle JR, Hoover RN, Yang CS,
Chhabra SK. CYP2E1 genetic polymorphisms and risk of nasopharyngeal
carcinoma in Taiwan. J Natl Cancer Inst 1997; 89:
12071212
22 Kiss
I, Sandor J, Pajkos G, Bogner B, Hegedus G, Ember I. Colorectal
cancer risk in relation to genetic polymorphism
of cytochrome P450
1A1, 2E1, and glutathione-S-transferase M1 enzymes. Anticancer
Res 2000; 20: 519522
23 Le
Marchand L, Donlon T, Seifried A, Wilkens LR. Red meat intake,
CYP2E1 genetic polymorphisms, and colorectal
cancer risk. Cancer
Epidemiol Biomarkers Prev 2002; 11: 10191024
24 Itoga
S, Nomura F, Makino Y, Tomonaga T, Shimada H, Ochiai T, Iizasa
T, Baba M, Fujisawa T, Harada S.
Tandem repeat polymorphism of the
CYP2E1 gene: An association study with esophageal cancer and lung
cancer.
Alcohol Clin Exp Res 2002; 26(8 Suppl): 15S19S
25 Wong
NA, Rae F, Simpson KJ, Murray GD, Harrison DJ. Genetic
polymorphisms of cytochrome p4502E1 and
susceptibility to alcoholic
liver disease and hepatocellular carcinoma in a white population: A
study and literature
review, including meta-analysis. Mol Pathol
2000; 53: 8893
26 Murata
M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, Katoh T,
Kamataki T, Kawamura J, Yatani R,
Shiraishi T. Genetic polymorphisms
in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase
(GST)
M1 and GSTT1 and susceptibility to prostate cancer in the
Japanese population. Cancer Lett 2001; 165: 171177
27 Kim
JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, Min HK, Lee JM,
Namkoong SE. Combined analysis of germline
polymorphisms of p53,
GSTM1, GSTT1, CYP1A1, and CYP2E1: Relation to the incidence rate of
cervical carcinoma.
Cancer 2000; 88: 20822091
28 El-Serag
HB, Mason AC, Petersen N, Key CR. Epidemiological differences
between adenocarcinoma of the
oesophagus and adenocarcinoma of the
gastric cardia in the USA. Gut 2002; 50: 368372
29 Kato
S, Shields PG, Caporaso NE, Hoover RN, Trump BF, Sugimura H,
Weston A, Harris CC. Cytochrome P450IIE1
genetic polymorphisms,
racial variation, and lung cancer risk. Cancer Res 1992; 52:
67126715
30 Kelley
JR, Duggan JM. Gastric cancer epidemiology and risk factors. J
Clin Epidemiol 2003; 56: 19
31 Kubo
A, Corley DA. Marked regional variation in adenocarcinomas of
the esophagus and the gastric cardia in the
United States. Cancer
2002; 95: 20962102
32 Engel
LS, Vaughan TL, Gammon MD, Chow WH, Risch HA, Dubrow R, Mayne
ST, Rotterdam H, Schoenberg JB,
Stanford JL, West AB, Blot WJ,
Fraumeni JF Jr. Occupation and risk of esophageal and gastric cardia
adenocarcinoma.
Am J Ind Med 2002; 42: 1122
33 Engel
LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL,
Schoenberg JB, Mayne ST, Dubrow R,
Rotterdam H, West AB, Blaser M,
Blot WJ, Gail MH, Fraumeni JF Jr. Population attributable risks of
esophageal and
gastric cancers. J Natl Cancer Inst 2003; 95:
14041413
34 Terry
MB, Gaudiest MM, Gammon MD. The epidemiology of gastric cancer. Semin
Radiat Oncol
2002; 12: 111127
35 Chao
A, Thun MJ, Henley SJ, Jacobs EJ, McCullough ML, Calle EE.
Cigarette smoking, use of other tobacco products
and stomach cancer
mortality in US adults: The Cancer Prevention Study II. Int J
Cancer 2002; 101: 380389
36 Gonzalez
CA, Pera G, Agudo A, Palli D, Krogh V, Vineis P, Tumino R,
Panico S, Berglund G, Siman H, Nyren O,
Agren A, Martinez C,
Dorronsoro M, Barricarte A, Tormo MJ, Quiros JR, Allen N, Bingham S,
Day N, Miller A,
Nagel G, Boeing H, Overvad K, Tjonneland A,
Bueno-De-Mesquita HB, Boshuizen HC, Peeters P, Numans M,
Clavel-Chapelon F, Helen I, Agapitos E, Lund E, Fahey M, Saracci R,
Kaaks R, Riboli E. Smoking and the risk of
gastric cancer in the
European Prospective Investigation Into Cancer and Nutrition (EPIC).
Int J Cancer
2003; 107: 629634
37 Sasazuki
S, Sasaki S, Tsugane S. Cigarette smoking, alcohol consumption
and subsequent gastric cancer risk by
subsite and histologic type. Int
J Cancer 2002; 101: 560566
38 Glatt
HR. An overview of bioactivation of chemical carcinogens. Biochem
Soc Trans 2000; 28: 16
39 Indulski
JA, Lutz W. Metabolic genotype in relation to individual
susceptibility to environmental carcinogens.
Int Arch Occup
Environ Health 2000; 73: 7185
40 Cai
L, Yu SZ, Zhang ZF. Glutathione S-transferases M1, T1 genotypes
and the risk of gastric cancer: A
case-control study. World J
Gastroenterol 2001; 7: 506509
41 Augenlicht
LH, Heerdt BG, Mariadason JM, Yang W, Wilson AJ, Fragale A,
Velcich A. Environment-gene interactions
in intestinal cancer. Eur
J Cancer Prev 2002; 11(Suppl 2): S12-S17
42 Malats
N. Gene-environment interactions in pancreatic cancer. Pancreatology
2001; 1: 472476
43 Kiyohara
C. Genetic polymorphism of enzymes involved in xenobiotic
metabolism and the risk of colorectal cancer.
J Epidemiol
2000; 10: 349360
44 Agundez
JA. Cytochrome p450 gene polymorphism and cancer. Curr Drug
Metab 2004; 5: 211224
45 Neuhaus
T, Ko YD, Lorenzen K, Fronhoffs S, Harth V, Brode P, Vetter H,
Bolt HM, Pesch B, Bruning T. Association
of cytochrome P450 2E1
polymorphisms and head and neck squamous cell cancer. Toxicol
Lett 2004; 151: 273282
46 Munaka
M, Kohshi K, Kawamoto T, Takasawa S, Nagata N, Itoh H, Oda S,
Katoh T. Genetic polymorphisms of
tobacco- and alcohol-related
metabolizing enzymes and the risk of hepatocellular carcinoma.
J
Cancer Res Clin Oncol 2003; 129: 355360
47 Mizoue
T, Tokui N, Nishisaka K, Nishisaka S, Ogimoto I, Ikeda M,
Yoshimura T. Prospective study on the relation
of cigarette smoking
with cancer of the liver and stomach in an endemic region. Int J
Epidemiol 2000; 29: 232237
48 Kikuchi
S, Kurosawa M, Sakiyama T, Tenjin H. Long-term effect of smoking
on serum pepsinogen values.
J Epidemiol 2002; 12:
351356
49 Hecht
SS, Carmella SG, Chen M, Dor Koch JF, Miller AT, Murphy SE,
Jensen JA, Zimmerman CL, Hatsukami DK.
Quantitation of urinary
metabolites of a tobacco-specific lung carcinogen after smoking
cessation.
Cancer Res 1999; 59: 590596
50 Hecht
SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer
Inst 1999; 91: 11941210
51 Hecht
SS. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat
Res 1999; 424: 127142
52 Mori
Y, Koide A, Kobayashi Y, Morimura K, Kaneko M, Fukushima S.
Effect of ethanol treatment on metabolic
activation and
detoxification of esophagus carcinogenic N-nitrosamines in rat
liver. Mutagenesis 2002; 17: 251256
53 Godschalk
R, Nair J, van Schooten FJ, Risch A, Drings P, Kayser K,
Dienemann H, Bartsch H. Comparison of
multiple DNA adduct types in
tumor adjacent human lung tissue: Effect of cigarette smoking. Carcinogenesis
2002; 23: 20812086
54 Yoshimura
K, Hanaoka T, Ohnami S, Ohnami S, Kohno T, Liu Y, Yoshida T,
Sakamoto H, Tsugane S. Allele
frequencies of single nucleotide
polymorphisms (SNPs) in 40 candidate genes for gene-environment
studies on cancer:
Data from population-based Japanese random
samples. J Hum Genet 2003; 48: 654658
55 Tan
W, Song N, Wang GQ, Liu Q, Tang HJ, Kadlubar FF, Lin DX. Impact
of genetic polymorphisms in cytochrome
P450 2E1 and glutathione S-transferases
M1, T1, and P1 on susceptibility to esophageal cancer among
high-risk
individuals in China. Cancer Epidemiol Biomarkers Prev
2000; 9: 551556
Science Editor Li WZ
Language Editor Elsevier HK
| |